Instylla
Distilling a Brand for a Refresh
Instylla's minimally invasive treatment for hypervascular tumors and hemorrhage stops disease in its tracks, restoring hope to the world's sickest patients. Sprig Consulting and Waltz Creative partnered to evolve this medtech brand to the next level in its marketing efforts, delivering integrated strategy and creative execution that drove measurable growth. Sprig developed comprehensive messaging frameworks and market positioning, while Waltz simplified the original corporate logo, expanded the visual system, and created cohesive brand applications across all touchpoints.
- Brand Development & Strategy
- Website Design & Development
- Packaging Design
- Media Presentations & Sales Materials
- Marketing Collateral & Event Assets
- Social Media & Digital Campaigns
Strategic Foundation & Visual Evolution
The Sprig team established Instylla's brand foundation through comprehensive messaging frameworks, conjoint analyses for positioning, and leadership alignment sessions. This strategic groundwork ensured all creative executions would resonate with target audiences and support business objectives.
Building on Sprig's strategic direction, Waltz evolved Instylla's visual identity through logo refinement, expanded color palette, and comprehensive graphic system. This cohesive approach created professional brand consistency across all applications without requiring a complete rebrand. The refreshed identity was applied to a new website, packaging, presentation decks and more.
Integrated Campaign Execution
The partnership delivered seamless execution across multiple channels, from event marketing and social amplification to customer-ready sales assets. Sprig coordinated targeted campaigns and KOL engagement while Waltz created supporting animations, videos, and collateral that drove booth traffic and engagement.
Measured Results
Through integrated KPI tracking, the team monitored engagement metrics, conversion signals, and awareness indicators, demonstrating measurable growth in social reach, website traffic, and event impact while supporting Instylla's annual planning cycles. Success has continued after the initial campaigns, with Instylla achieving several milestones, including completing clinical trials, securing a $30MM round of EQUITY Financing and gaining U.S. FDA Premarket Approval for the Embrace™ Hydrogel Embolic System.
